Biotech China 2014
EpiCongress Boston
DoubleTree Suites by Hilton Hotel Boston
400 Soldiers Field Road
Boston, USA
http://epic-boston.com/
EpiCongress Boston
Hanson Wade
http://epic-boston.com/
DoubleTree Suites by Hilton Hotel Boston
400 Soldiers Field Road
Boston
USA

Schedule of Presentations:

Tuesday, July 23, 2013
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
09:00:00 Epigenomics Data Management and Visualization Strategies
13:00:00 Bridging Epigenetic Mechanisms and Stem Cell Biology Zong Ling Wang
Wednesday, July 24, 2013
06:00:00 New Presentation
06:00:00 New Presentation
08:15:00 Chairman’s Opening Remarks
08:30:00 An update on Epizyme’s first clinical candidate molecule Robert Gould
09:00:00 Developing Specific Assays to Bridge the Knowledge Gap in Epigenetic Pathways
09:30:00 Epigenetic Drug Discovery: Are we Inspired by History or Deluded by it?
10:00:00 Morning Refreshments & Speed Networking
11:30:00 Exploring Histone Methyltransferase EZH2 as an Epigenetic Target For Cancer Therapy Caretha Creasy
11:30:00 Clinical Case Study: Using PK/PD Endpoints for Dose-Ranging in Early Clinical Development of Epigenetic Drugs
11:30:00 Genetic Drivers of Altered Epigenomic States in B Cell Lymphoma: Opportunities for Therapeutic Manipulation Russell J. H. Ryan
12:00:00 A Candidate Gene Approach to Exploring the Role of DNA Methylation in Breast Cancer Disparities Garth Rauscher
12:00:00 Methylomic Alterations in Pathogenesis and Classification of Cancer Amit Verma
12:00:00 Therapeutic Opportunities for EZH2 Histone Methyltransferases in Blood Malignancies and Lymphoma
12:30:00 Discovery and Development of a Mechanism-Based Epigenetic Biomarker for Lung Cancer Trials David Shames
12:30:00 Translating Chromatin Modulation To Drug Discovery: Inhibition Of EZH2
12:30:00 Defining the Functional Consequences of Isoform Specific Inhibition of the Class I HDACs Using a Chemical Genetics Approach Edward Holson
13:00:00 Lunch & Networking
13:00:00 Panel Discussion: Discovering Clinic Biomarkers and Improving Patient Selection
13:00:00 Lunch & Networking
13:30:00 Lunch & Networking
14:00:00 Translational Development of Second Generation Class Selective HDACi’s: Analogs of the Natural Product Largazole John Pilon
14:00:00 The Therapeutic Potential of Jumonji Histone Demethylase Inhibitors Peter Staller
14:30:00 Discovery and Development of Specific LSD1 Inhibitor Sunil Sharma
14:30:00 Targeting on Epigenetic Reader for Cancer Therapy Jun Qi
14:30:00 Panel Discussion: Developing Specific Epigenetic Assays Peter Staller
15:00:00 RVX-208; the First BET-Protein Inhibitor Tested in Human Clinical Trials
15:30:00 Afternoon Refreshments & Networking
16:00:00 Using Computational Analysis to Map out the Drugability Landscape of Epigenetic Targets
16:30:00 Using Chemical Probes to Aid Epigenetic Target Validation - unpublished data Mark Bunnage
17:00:00 Panel Discussion: Improving Target Validation and Prioritization Holger Patzke, Peter J Tummino
17:30:00 Chairman’s Closing Remarks
17:45:00 Poster Session - Present your latest work to the audience during our open poster session
Thursday, July 25, 2013
06:00:00 New Presentation
08:45:00 Chairman’s Opening Remarks Mark Bunnage
09:00:00 Selective Inhibitors of HDAC1/2 and Induction of Fetal Globin: Novel Treatment for Sickle Cell Disease and β-Thallasemia Simon Jones
09:30:00 Chemogenomic Approaches To Spatiotemporal Regulation Of HDAC Activity
10:00:00 Morning Refreshments & Networking
10:30:00 Prospects for BET Inhibitors in Solid Tumors Peter J Tummino
10:30:00 Genome Regulation in Health and Disease Richard Young
10:30:00 Targeting the Substrate Binding Site of Methyltranferases: Structure Based Design of SMYD2 Inhibitors Scott Cowen
11:00:00 Discovering Chemical Probes of Histone Methyltransferases Jian Jin
11:00:00 Chromatin Maps and Epigenomic Features of Normal and Malignant Hematopoietic Development Mazhar Adli
11:00:00 Epigenetic Regulation Of Resistance To Anti-Cancer Drugs Jeffrey Settleman
11:30:00 Recruitment of Chromatin Modifying Activities by DNA binding proteins Jinrong Min
11:30:00 Targeting the SAM Binding Sites of Methyltranferases to Identify Novel Inhibitors Kenneth J. Eilertsen
11:30:00 Selecting Patients for Entinostat in a Phase 2 Trial Peter Ordentlich
12:00:00 Lunch & Networking
12:00:00 Lunch & Networking
12:00:00 Lunch & Networking
13:00:00 The Promise of Epigenetic Therapy in Solid Tumors – Lessons Being Learned from Current Drugs Stephen B Baylin
13:00:00 Selectively Activating Gene Expression by Targeting Non-Coding RNA
13:30:00 CC-486 Priming in Solid Tumors to Improve Chemotherapy Efficacy
13:30:00 Coming to Grips with Heterogeneity in Neuropsychiatric Disorders: Epigenetic Analytic and Therapeutic Approaches Curtis Deutsch
13:30:00 Thinking Outside the Box when Developing Chromatin Interacting Drugs Steven Landau
14:00:00 Cancer, Schizophrenia and Autism: Comparing Environmental and Epigenomic Components
14:00:00 Afternoon Refreshments & Networking
14:30:00 How is the SGC Helping To Push Innovation in the Field? Cheryl Arrowsmith
15:00:00 Investing in Epigenetics: A Venture Capitalist Perspective on Raising Long Term Funding
15:30:00 Realizing the Potential for the First-in-Class Selective LSD1 Inhibitor Jonathan Northrup
16:00:00 Chairman’s Closing Remarks & Close of Conference Mark Bunnage
Friday, July 26, 2013
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
09:00:00 Translating Epigenetic Regulation to Clinical Oncology Hella Kohlhof
13:00:00 Pathway-based Application of Epigenetic Drugs to Optimize Clinical Safety and Efficacy
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.